Sex-specific considerations in nanomedicine: highlighting the impact of the menstrual cycle on drug development.

clinical trials drug development hormonal changes menstrual cycle nanomedicine nanoparticles protein corona sex differences sex-specific analysis women's health

Journal

Nanomedicine (London, England)
ISSN: 1748-6963
Titre abrégé: Nanomedicine (Lond)
Pays: England
ID NLM: 101278111

Informations de publication

Date de publication:
03 2024
Historique:
medline: 12 3 2024
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: ppublish

Résumé

Tweetable abstract The female menstrual cycle is one of the most overlooked sex-specific factors in drug distribution and response. Unlocking the potential of nanomedicine demands a fundamental understanding of the impact biological sex has on drug distribution, efficacy and adverse effects.

Identifiants

pubmed: 38127525
doi: 10.2217/nnm-2023-0347
doi:

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

557-560

Auteurs

Maria Poley (M)

Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Department of Medicine, Division of Engineering in Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH